Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This keeps breaking out, then consolidating, then breaking out again. The price touched 26 after hours, so that may be my price target, however, I may get out at 24. I watch the price action closely.
It's trading pretty normally right now..nothing too unexpected
many thanks for the INFO
Im in on this. Huge volume spike. We are creating new intraday support right now. I think this has the potential to run. We'll see...
7:05AM Biogen Idec and Sangamo (SGMO) announce exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin (BIIB) 290.01 :
Co and Sangamo BioSciences (SGMO) announced an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin. The agreement will enable Biogen Idec to further enhance its expertise in non-malignant hematology by leveraging Sangamo's proprietary genome-editing technology platform to develop treatments targeting sickle cell disease and beta-thalassemia.
Biogen Idec will provide Sangamo with an upfront payment of $20 million and will reimburse Sangamo for its internal and external research and development program-related costs. Sangamo may also receive additional payments of ~ $300 million based on the achievement of certain development, regulatory, commercialization and sales milestones, as well as double digit royalties on product sales.
7:10AM Sangamo BioSci presents data from non-human primates providing proof of concept for disruptive and broadly leverageable platform for Protein Replacement Therapies; Therapeutic Levels of gene modification in Sangamo's In Vivo Protein Replacement Platform (SGMO) 12.40 : Co announced the presentation of new pre-clinical data demonstrating therapeutic levels of gene modification in non-human primates (NHPs) from its In Vivo Protein Replacement Platform. Based on Sangamo's zinc finger DNA-binding protein (ZFP) genome-editing technology, the platform enables the permanent production of therapeutic proteins from a specific genomic site in the liver with a single systemic treatment, potentially providing curative treatments for a range of monogenic diseases such as hemophilia and lysosomal storage disorders (LSD) including Gaucher and Fabry disease. Such diseases are currently treated by regular infusions of protein or enzyme replacement therapy (ERT) throughout the patient's life. The data were presented at the 55th Annual Meeting of the American Society of Hematology (ASH) which is being held in New Orleans.
"These data provide proof of concept for this broadly applicable genome editing strategy by demonstrating that our process is scalable to large animals and by validating the use of the albumin safe harbor as a site for expression of therapeutic proteins," said Philip Gregory. D. Phil., Sangamo's vice president of research and chief scientific officer. "We have further optimized Sangamo's ZFN system and demonstrated that a single systemic treatment enables stable liver-specific production of replacement protein. Early data in primates suggest that we can achieve circulating levels of protein above the threshold for therapeutic effect, which we believe are sufficient for the correction of a range of monogenic diseases. Our data demonstrate expression of replacement enzymes for multiple different proteins, including those deficient in lysosomal storage disorders, which serves to demonstrate the potential of this approach for a broad range of other monogenic diseases."
7:05AM Sangamo BioSci announces presentation of first demonstration of in vivo efficacy of novel ZFP therapeutic for huntington's disease; approach selectively represses only the disease-causing gene resulting in statistically significant effects on symptoms and other biomarkers of disease in animal models (SGMO) 9.69 : The data demonstrate that Sangamo's zinc finger DNA-binding protein gene regulation technology can be used to selectively repress the expression of the mutant and disease-causing form of the huntingtin gene (HTT) leaving the normal gene unchanged in a mouse model (R6/2) of the disease. This selective repression has positive effects on both molecular markers and physical indications of disease in the animals. In the ZFP Therapeutic-treated regions of the animals' brains, scientists observed a reduction of mutant huntingtin protein aggregates, levels of which are associated with the severity of the disease in humans. Sangamo scientists also observed increased levels of biomarkers indicative of protection of critical nerve cells that are progressively lost in the brains of HD patients. Delivery of the ZFP Therapeutic to the brain of R6/2 mice resulted in a statistically significant reduction in "clasping behavior" compared to controls. "Clasping" is an HD-associated symptom exhibited by R6/2 animals that mimics the motor symptoms of the human disease.
Sangamo scientists designed and engineered zinc finger transcription factors (ZFP TFs) targeting the expanded CAG repeat, the genetic signature of HD. In multiple independent cell lines derived from HD patients carrying different, disease-causing CAG repeat lengths, they demonstrated that these ZFP TFs decreased production of the mutant HTT messenger RNA (mRNA) by >90% while leaving the levels of the normal HTT mRNA largely unchanged; in turn, this achieved similar selective reduction in levels of mutant protein compared to normal HTT protein. Delivery of these ZFP TFs to a region of the brain, the striatum, in mouse models of the disease, resulted in a statistically significant decrease (p<0.001) in production of the mutant huntingtin but not the normal form of the protein.
ZFP-treatment also resulted in biomarker changes indicative of preservation of medium spiny neurons, the nerve type in the striatum that is primarily lost in HD, as well as a reduced appearance of aggregates of mutant huntingtin protein, which are thought to be a major cause of nerve dysfunction. Importantly, these molecular changes were accompanied by statistically significant improvements (p<0.05), compared to controls, in "clasping behavior" symptoms in the mouse model that mimic the motor symptoms of the human disease.
Sangamo BioSciences Proposes Public Offering Of Common Stock
RICHMOND, Calif., Sept. 17, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Sangamo also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. All of the shares in the offering are to be sold by Sangamo.
(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)
Lazard Capital Markets LLC, JMP Securities LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering.
A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on April 12, 2012. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. When available, copies of the preliminary prospectus supplement relating to these securities may also be obtained from the offices of Lazard Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor, New York, NY 10020 or via telephone at 800-542-0970; or JMP Securities LLC, Attention: Prospectus Department, 600 Montgomery Street, 10th Floor, San Francisco CA 94111, or via telephone at 415-835-8985; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis MN 55402, or via telephone at 800-747-3924.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase 1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia and hemoglobinopathies such as sickle cell anemia and beta-thalassemia, and a program in Huntington's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases, and it has also established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com
ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, the proposed public offering of shares of common stock. Actual results may differ materially from these forward-looking statements due to a number of factors, including risks and uncertainties related to whether or not Sangamo will be able to raise capital through the sale of shares of common stock, the final terms of the proposed offering, market and other conditions for the offering, and the satisfaction of customary closing conditions related to the proposed public offering. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to Sangamo and its business can be found under the heading "Risk Factors" in Sangamo's Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q, and in the preliminary prospectus supplement related to the proposed offering to be filed with the SEC on or about the date hereof. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.
Didn't SGMO have an abstract today at ICAAC? I know the late breaker is tomorrow. Thought there was one today too from 11:30 to 1. Huge bid appeared around 2 today.
7:01AM Sangamo BioSci announces notice of allowance for new patent application covering genome modification technology (SGMO) 10.00 : Co announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent application entitled "Novel DNA-binding Proteins and Uses Thereof." The claims cover core architectural aspects of engineered Transcription Activator-Like Effectors, or TALEs, which enable these proteins to be useful in potential therapeutic applications of genome editing or gene regulation and for the efficient use of the technology in biomedical research and plant applications.
10-July JMP Conference Updates
Interesting remarks...
Transcript here
7:12AM Sangamo BioSci receives $6.4 mln strategic partnership award from California Institute for Regenerative Medicine to develop ZFP Therapeutic for beta-thalassemia (SGMO) 7.93 : Co announced that the California Institute for Regenerative Medicine (CIRM) has granted the co a $6.4 million Strategic Partnership Award to develop a potentially curative ZFP Therapeutic for beta-thalassemia based on the application of its zinc finger nuclease gene-editing technology in hematopoietic stem cells. The four year grant provides matching funds for preclinical work that will support an Investigational New Drug (IND) application and a Phase 1 clinical trial in transfusion-dependent beta-thalassemia patients.
10:01AM Sangamo BioSci presents clinical data demonstrating HIV reservoir reduction in HIV-infected subjects treated with ZFP Therapeutic, ZB-728-T (SGMO) 8.81 -0.07 : Co announced the presentation of new clinical data from its program to develop a ZFP Therapeutic for HIV/AIDS. The data, which demonstrate that SB-728-T treatment results in a reduction in the HIV reservoir in HIV-infected subjects, are being presented at the 16th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). The meeting is being held in Salt Lake City from May 15-18, 2013. HIV-infected subjects enrolled in Sangamo's ongoing SB-728-902 clinical trial (Cohorts 1-3) received a single infusion of SB-728-T which resulted in a durable increase in total CD4 T-cells driven by increased ZFN-modified CD4 central memory T-cells. The extent of exposure of subjects to circulating zinc finger nuclease (ZFN) CCR5 protected CD4 T cells correlated with a long term decrease in the peripheral blood mononuclear cell (PBMC) HIV reservoir as measured by proviral DNA. In addition, two of four evaluable subjects in Cohort 5 of this study showed a decrease of greater than one log in their viral load during a sixteen week treatment interruption (TI) with one of the subjects achieving a transiently undetectable viral load during the TI period. In subjects in which viral load decreased, a measureable anti-HIV response was observed, specifically a multi-functional response of CD8 T-cells to elements of HIV core proteins.
Its not there.
Either wrong link or they removed it
Sangamo BioSci SGMO BioLogic Equity Research Sell
http://www.breifing.com/investor/calendars/upgrades-downgrades/
NOW THATS HOW U MOVE A STOCK $$$ whhooo!
phase II trial only has 15 patients on one side, so the next news will read.."not enough peeps in the trial to have a credible result!!! what a joke., but they buy a half of a year, with peeps stuck in this @ 8...joke!
sgmo...getting crushed today...wow, guess they dont have a real treatment huh?
4:21PM Sangamo BioSci beats by $0.05, beats on revs; guides FY13 revs in-line (SGMO) 9.42 +0.05 : Reports Q4 (Dec) loss of $0.07 per share, $0.05 better than the Capital IQ Consensus Estimate of ($0.12); revenues rose 88.4% year/year to $8.93 mln vs the $5.95 mln consensus. Co issues in-line guidance for FY13, sees FY13 revs of $20-24 mln vs. $23.08 mln Capital IQ Consensus Estimate.
My opinion of today’s CC, FWIW: #msg-84292642.
Anyone feel we will get word on late abstract admission before the Feb 6th earnings? EL seemed so pumped up recently that I got the impression he was BUSTING to reveal something....very early.
Sangamo BioSciences: A Biotech Not To Be Shorted
http://seekingalpha.com/article/1112331-sangamo-biosciences-a-biotech-not-to-be-shorted?source=yahoo
Sangamo BioSciences: A Potentially Revolutionary 2013
http://seekingalpha.com/article/1112651-sangamo-biosciences-a-potentially-revolutionary-2013?source=yahoo
PLEASE HELP: What site (paid or free) you use to see the L2 Live?
Other than ihub. Please help?
Thanks
New article... Sangamo BioSciences: A Potentially Revolutionary 2013
http://propthink.com/sangamo-biosciences-a-potentially-revolutionary-year/4628
4:34PM Sangamo BioSci announces presentation of data demonstrating a disruptive and broadly leverageable platform for protein replacement therapies at ASH meeting (SGMO) 6.06 +0.13 : Co announced the presentation of new pre-clinical data demonstrating the successful application of its In Vivo Protein Replacement Platform. Based on Sangamo's zinc finger DNA-binding protein (ZFP) genome-editing technology, the platform enables the permanent production of therapeutic proteins from the liver with a single systemic treatment, potentially providing curative treatments for a range of monogenic diseases including hemophilia and lysosomal storage diseases (LSD) such as Gaucher, and Fabry disease. Such diseases are currently treated by regular infusions of protein or enzyme replacement therapy (ERT) throughout the patient's life. The data were presented at the 54thAnnual Meeting of the American Society of Hematology (ASH) which is being held in Atlanta.
4:09PM Sangamo BioSci reaffirms anticipated amount of cash and cash equivalent of $40-45 mln by the end of 2015 assuming completion of milestones with existing partnerships (SGMO) 5.41 -0.01 :
4:09PM Sangamo BioSci provides an update on its technology platform advancements and pipeline of ZFP Therapeutics (SGMO) 5.41 -0.01 : Co announced that the company is providing an update on its technology platform advancements and pipeline of ZFP Therapeutics as well as near- and mid-term operating goals during an Analyst and Investor Briefing being held today in New York City. Sangamo plans to present preliminary data in the first half of 2013 from its clinical trials of SB-728-T (SB-728-1101 and SB-728-902 Cohort 5) for the treatment of HIV/AIDS and expects to have the full data set from these trials by the end of 2013. Sangamo will outline its strategy to enable the potential filing of seven Investigational New Drug (IND) Applications by the end of 2015. The Company will introduce a new, highly disruptive "In Vivo Protein Replacement Platform" driven by Sangamo's ZFP nuclease (ZFN) technology which is potentially curative and leverageable across many monogenic diseases, such as hemophilia and LSDs (e.g. Gaucher, Fabry, and Pompe disease) that are currently treated by regular infusions of enzyme replacement therapy (ERT). Sangamo will provide a near- and mid-term financial overview including the anticipated amount of cash and cash equivalent of $40-$45 million by the end of 2015 assuming completion of milestones associated with existing partnerships but not including any additional funding from new partnerships, research grants or equity financing transactions.
Sangamo BioSciences, Inc. [SGMO] to Ring The NASDAQ Stock Market Closing Bell
10:00 AM ET 12/5/12 | GlobeNewswire
What:
Sangamo BioSciences, Inc. [SGMO], researcher and developer of novel DNA-binding proteins for therapeutic genome editing and gene regulation, will visit the NASDAQ MarketSite in Times Square.
In honor of the occasion, Edward Lanphier, President and CEO will ring the Closing Bell.
Where:
NASDAQ MarketSite -- 4 Times Square -- 43rd& Broadway -- Broadcast Studio
When:
Thursday, December 6, 2012 -- 3:45 p.m. to 4:00 p.m. ET
Contact: Elizabeth Wolffe (510) 970-6000 x271 ewolffe@sangamo.com
Zinc,
I know very little about SGMO. I have been a Type I Diabetic for 42 years, and I am always hoping/praying for a cure. My doctors, over the years since 1970, have been telling me that a cure is coming. It is all BS.
Therefore, my curisoity has been piqued by SGMO as it makes its way to curing some of the dreaded diseases of humaity. Do you know if there is any research being done by SGMO to cure this God-forsaken Type I Diabetes?
Sangamo BioSciences (SGMO) has several "function cures" of HIV in its clinical trials. SGMO has protected IP in the zinc finger nuclease and TALENs gene-editing platforms. These platforms are "disruptive" in that they represent a way to cure several diseases, rather than treat them. More: http://bit.ly/WayJpR
7:07AM Sangamo BioSci announces first presentation of data from ZFP Therapeutic for Huntington's Disease at 2012 annual meeting of society for neuroscience; novel zfp therapeutic approach selectively represses only the disease-causing gene (SGMO) 5.85 : The data demonstrate that a ZFP Therapeutic, based on Sangamo's zinc finger DNA-binding protein (ZFP) gene regulation technology, can selectively repress the expression of the mutant disease-causing form of the huntingtin gene (HTT) while leaving expression levels of the normal gene unchanged in cells derived from HD patients. In multiple independent cell lines derived from HD patients carrying different, disease-causing CAG repeat lengths, they demonstrated that these ZFP TFs decreased production of the mutant HTT messenger RNA (mRNA) by >90% while leaving the levels of the normal HTT mRNA largely unchanged (a reduction of 10% or less); in turn, this achieved similar selective reduction in levels of mutant compared to normal HTT protein. Furthermore, in neurons derived from a HD mouse model (R6/2), ZFP TFs selectively repressed the expression of mutant HTT, which is required for disease expression in these animals. In strong support of the safety of this approach, an unbiased genome-wide expression analysis confirmed the exquisite specificity of the ZFP TFs targeted to the HTT CAG-repeat alone.
Sangamo BioSciences Announces Presentation of Clinical Data from ZFP Therapeutic® for HIV/AIDS at ICAAC 2012
Findings Demonstrate Immune Reconstitution and Potential Success of "Functional Cure" in HIV-Infected Individuals
PR NewswirePress Release: Sangamo BioSciences, Inc. – Mon, Sep 10, 2012 12:30 PM EDT
RICHMOND, Calif., Sept. 10, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (SGMO) announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for HIV/AIDS, were presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The meeting is being held in San Francisco from September 9-12, 2012.
"The immunologic data presented at ICAAC have predictive implications for the success of this exciting new therapeutic approach to HIV and the realization of a 'functional cure' for the disease," commented Rafick-Pierre Sékaly, Ph.D., Co-Director & Chief Scientific Officer, the Vaccine & Gene Therapy Institute of Florida (VGTI Florida), whose laboratory carried out the analysis. "SB-728-T treatment results in an unprecedented and durable increase in CD4+ cells. Importantly, our analysis shows that this is primarily due to the expansion of CD4+ T-cell types that are vital for the successful reconstitution of the immune system in HIV-infected individuals - the central and transitional memory cells."
"These data are very important because CD4 T-cells, especially memory T-cells, are precisely the cell type that we would want to protect and expand to enable HIV-infected individuals to control infections, and HIV, without antiretroviral drugs," added Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "Our aim is to provide a protected reservoir of immune memory cells to replenish the cells killed by HIV and to generate an effective immune response against the virus and opportunistic infections. Central and transitional memory T-cells remember previously encountered foreign invaders, such as viruses or bacteria. These cells can survive in the body for the individual's lifetime, and when they re-encounter the same antigen they reactivate, producing a faster and stronger immune response than the previous encounter. SB-728-T seems to both expand the total memory pool, and by CCR5 modification, protect a proportion of that pool from HIV entry, suggesting that SB-728 treatment has the potential to reconstitute and protect an effective and durable immune system in HIV-infected individuals."
SB-728-T is generated by ZFN-mediated modification of the gene encoding the CCR5 receptor in a patient's own T-cells, disrupting the expression of this key co-receptor for HIV entry and rendering the modified cells resistant to HIV infection.
In an oral presentation made on Monday, September 10th, 2012 at ICAAC, data were presented from all dosing cohorts of Sangamo's Phase 1 dose-escalation study (SB-728-902) in subjects on highly active antiretroviral therapy (HAART). The data demonstrate that SB-728-T infusion in HIV-infected subjects is well-tolerated, and results in significant and sustained increases in CD4+ T-cells above baseline throughout the year-long period reported in the study. Statistically significant improvement in CD4 counts were observed even at 12 months post infusion (p<0.038). In particular, CD4 counts improved to greater than 500 cells/mm3 in five of nine subjects in the study at one year post-treatment, which is the usual T-cell count threshold for initiation of HAART in HIV-infected subjects.
Analysis of the specific types of CD4 T-cells that comprise the initial increase in CD4+ T-cells post-infusion revealed that they were primarily transitional memory T-cells (TTM). The frequency of TTM expressing CD25 (a marker that identifies activated T-cells) within the SB-728-T product correlated with the peak CD4 count post-infusion (r=0.733, p=0.0172). This suggests that replication of activated TTM SB-728-T cells post-infusion accounts for the initial peak improvement in CD4+ T-cells. As the infused cells consist of only 1-10% of total memory cells at six months post-treatment, the prolonged increase in absolute numbers of CD4+ T-cells may be accounted for by the enhanced survival and differentiation of host central memory T-cells (TCM). Specifically, while the magnitude of the increase in TTM positively correlated with the peak of CD4+ T-cells in the first weeks post-infusion (r= 0.9, p=0.083), the increase in TCM correlated with the maintenance of high CD4+ T cell counts at later time points (r= 0.9, p=0.083). Proliferation of the SB-728-T product post-infusion was sustained over the year-long period reported in the study with median modified circulating cell numbers measured to be 2.04-fold relative to input at 7 days, 0.96-fold at 6 months and 1.15-fold at 1 year post-infusion.
These preliminary data confirm the prolonged engraftment of SB-728-T, and suggest that SB-728-T has the attributes to provide sustained improvement in the CD4 memory compartment and the potential to reconstitute the immune system in immune non-responders.
"Our Phase 1 trials continue to provide valuable insight into the durability and unprecedented effects of SB-728-T treatment on immune system health in HIV-infected individuals," said Geoff Nichol, M.B., Ch.B., Sangamo's executive vice president of research and development. "In addition we are making good progress in two Phase 2 clinical trials designed to maximize the engraftment of SB-728-T. We expect to present preliminary data in the first half of 2013 and a full data set in the second half of next year. The ground-breaking clinical data that we and our collaborators are generating continues to validate this treatment as a promising approach to provide a 'functional cure' for HIV/AIDS."
ICAAC Presentations
Abst.#H533: "Preferential expansion of transitional (TTM) and Central Memory(TCM) CD4 T-cells following adoptive transfer of ZFN CCR5 Modified Autologous CD4 T-cells."
Monday, September 10, 2012: Oral session 073 (H) New Antiretroviral Therapy: Bench to Bedside.
Abst.#H-1581: "Digital droplet PCR (DD) qPCR allows quantiation of HIV proviral DNA in aviremic HIV+ subjects on HAART treated with ZFN CCR5 modified autologous CD4 T-cells (SB-728-T)."
Tuesday, September 11, 2012, Poster Session 180 (H) HIV-I Resistance, Tropism and Novel Laboratory Methods
The presentation will describe a new highly sensitive method developed by Sangamo scientists that enables accurate quantification of very low copy numbers of HIV DNA genomes, which may be a useful tool for evaluating interventions targeting the HIV reservoir, particularly Sangamo's approach to a 'functional cure' for the disease. For a more complete description of the technique click here
About SB-728-T
Sangamo's drug, SB-728-T, is generated by ZFN-mediated modification of the gene encoding the CCR5 receptor in a patient's own T-cells. ZFN modification disrupts the expression of this key co-receptor for HIV entry and renders cells resistant to HIV infection. The approach is based on the observation that a naturally occurring mutation in the CCR5 gene, CCR5 delta-32, provides protection from HIV infection. Individuals in whom both copies of the CCR5 gene carry the delta-32 mutation are generally not susceptible to the most common strain of HIV.
The non-employee authors of these abstracts have no financial relationship with Sangamo.
I just dove in myself, 7 dollars soon i think.
Just bought in. Looks like there is life coming back to this orphan.
Form 8-K for SANGAMO BIOSCIENCES INC 27-Jun-2012
Change in Directors or Principal Officers, Submission of Matters to a Vote
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Adoption of Incentive Compensation Plan
On June 21, 2012, the Compensation Committee of the Board of Directors of Sangamo BioSciences, Inc. (the "Company") adopted the Sangamo BioSciences, Inc. Incentive Compensation Plan (the "Plan") as a performance-based cash bonus program for the Company's executive officers. The Compensation Committee will have discretion to implement one or more performance periods under the Plan, each of a duration determined by the Compensation Committee.
Except for the initial performance period occurring in the 2012 year, within the first ninety (90) days of each performance period, the Compensation Committee will establish the specific performance and individual objectives which must be attained in order for Plan participants to receive a bonus for that performance period. For each performance and individual objective, the Compensation Committee may set threshold, target and above-target levels of attainment. The Compensation Committee will then establish for each participant dollar levels for the bonus to which he may become entitled for that performance period based on the level at which the performance and individual objectives are actually attained.
Performance objectives established under the Plan will be based on one or more of the following criteria: (i) revenue, organic revenue, net sales, or new-product revenue or net sales, (ii) achievement of specified objectives in the discovery and development of the Company's technology or of one or more of the Company's products, (iii) achievement of specified objectives in the commercialization of one or more of the Company's products, (iv) achievement of specified objectives in the manufacturing of one or more of the Company's products, (v) expense targets, (vi) share price, (vii) total shareholder return,
(viii) earnings per share, (ix) operating margin, (x) gross margin, (xi) return measures (including, but not limited to, return on assets, capital, equity, or sales), (xii) productivity ratios, (xiii) operating income, (xiv) net operating profit, (xv) net earnings or net income (before or after taxes), (xvi) cash flow (including, but not limited to, operating cash flow, free cash flow and cash flow return on capital), (xvii) earnings before or after interest, taxes, depreciation, amortization and/or stock-based compensation expense,
(xviii) economic value added, (xix) market share, (xx) working capital targets,
(xxi) achievement of specified objectives relating to corporate partnerships, collaborations, license transactions, distribution arrangements, mergers, acquisitions, dispositions or similar business transactions, and (xxii) employee retention and recruiting and human resources management.
Individual performance objectives established under the Plan will be based on one or more of the following criteria: (i) the participant's contribution toward the achievement of a specific Company performance objective, (ii) the contribution of the business unit or division supervised by the participant toward the achievement of a specific Company performance objective, and
(iii) the Participant's development of professional skills.
A participant will not become entitled to a bonus under the Plan for a particular performance period unless the participant remains employed by the Company through the date bonuses are paid to each participant following completion of that performance period. Following the close of the applicable performance period, the Compensation Committee will determine the actual bonus amount for each participant based on the actual levels at which the actual performance objectives are attained, and bonuses will be paid promptly following the end of the applicable performance period.
Should a change in control transaction be consummated prior to the completion of that performance period, then the performance period will terminate upon the consummation of that change in control and each participant in the Plan will receive a bonus in the dollar amount previously set by the Compensation Committee at target level attainment of each performance objective, however such bonus will be pro-rated to reflect each participant's actual period of service from the start date of the performance period through the effective date of the change in control. In the event a participant becomes eligible to receive a severance payment, the amount of which is based in part on the Participant's target bonus under the Plan, in connection with the participant's cessation of service in the year in which such change in control transaction is consummated, the pro-rated bonus paid pursuant to the terms of the Plan will reduce the amount of severance payable to the participant pursuant to the terms of such employment agreement.
In the event any payment to which a participant becomes entitled under the Plan would otherwise constitute a parachute payment under Section 280G of the Internal Revenue Code (the "Code"), then that payment will be subject to reduction to the extent necessary to assure that such payment will be limited to the greater of (i) the dollar amount which can be paid to the participant without triggering a parachute payment under Code Section 280G or (ii) the dollar amount of that payment which provides the participant with the greatest after-tax amount after taking into account any excise tax the participant may incur under Code Section 4999 with respect to such payment and any other benefits or payments to which the participant may be entitled in connection with any change in control of the Company or the subsequent termination of the participant's employment.
The foregoing summary does not purport to be a complete description of the Plan and is qualified in its entirety by reference to such Plan, which is filed as Exhibit 10.1 to this Current Report on Form 8-K.
Adoption of Fiscal Year 2012 Bonus Program
Upon adoption of the Plan, the Compensation Committee re-approved the bonus program previously established by the Compensation Committee for the 2012 year and brought such bonus program under the terms and conditions of the Plan. In connection with such re-approval, the corporate performance objectives previously approved by the Compensation Committee were not changed. In addition, the amount of each executive officer's target bonus was not changed; however, the Compensation Committee modified the bonus program for Philip Gregory, our Vice President, Research and Chief Scientific Officer and Dale Ando, our Vice President, Therapeutic Development and Chief Medical Officer in order to condition 20% of the target bonus payable to Dr. Gregory and Dr. Ando upon the achievement of the individual performance objectives.
For the performance period under the Plan coincident with the 2012 calendar year, the target cash bonus for our executive officers is as follows: Edward Lanphier II, our Chief Executive Officer, 50% of base salary; Ward Wolff, our Executive Vice President and Chief Financial Officer and Geoffrey Nichol, our Executive Vice President, Research and Development, 40% of base salary; Dr. Gregory and Dr. Ando, 30% of base salary.
For Mr. Lanphier, Mr. Wolff and Dr. Nichol, 100% of the target bonus will be earned on the basis of pre-established corporate performance objectives; for Drs. Gregory and Ando, 80% of the target bonus will be earned on the basis of corporate performance objectives and 20% of the target bonus will be earned on the basis of individual performance objectives. The Company must achieve a minimum of 70% of the corporate performance objectives for any bonuses to become payable. There is an opportunity for achievement of the corporate performance objective at a level above 100% in the event of exceptional performance; in particular, the weighting of the research objectives and corporate development objectives will exceed the indicated weighting in the event particular corporate objectives are achieved.
The corporate performance objectives and weighting for the 2012 year are as follows:
Corporate Performance Objectives Weighting
Clinical Objectives: 30 %
? Advance clinical trials of SB-728-T program in HIV/ AIDS
Development Objectives: 10 %
? Advance development pipeline of preclinical ZFP Therapeutic
? candidates
Business/Corporate Development Objectives: 30 %
? Complete at least one ZFP Therapeutic corporate partnership
? Other organization and business development goals
Research Objectives: 25 %
? Initiate and advance prioritized ZFP Therapeutic research
programs
Finance Objectives: 5 %
? Conclude 2012 with approximately $60 million in cash and
cash equivalents excluding cash from new corporate partnerships
or financing activities
Total 100 %
. . .
Item 5.07. Submission of Matters to a Vote of Security Holders.
The annual meeting of the Company's stockholders (the "Annual Meeting") was held on Thursday, June 21, 2012 for the purposes of (i) electing seven directors to serve on the board of directors of the Company for a one-year term; and
(ii) ratifying the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2012. There were present at the meeting, in person or represented by proxy, the holders of 42,520,565 shares of common stock, constituting a quorum. At the Annual Meeting, the stockholders elected the nominees for director listed in the proxy statement for the Annual Meeting and ratified the appointment of Ernst & Young LLP. The final vote on the proposals was recorded as follows:
Proposal No. 1: Election of Directors
Each of the nominees for director listed in the proxy statement for the Annual Meeting was elected by the votes set forth in the table below:
Votes Broker
Director Nominees Votes For Withheld Non-Votes
Edward O. Lanphier 17,145,461 230,122 25,144,782
Paul B. Cleveland 16,927,890 447,693 25,144,782
Stephen G. Dilly, M.B.B.S., Ph.D. 17,184,955 190,628 25,144,782
John W. Larson 16,776,449 599,134 25,144,782
Steven J. Mento, Ph.D. 17,097,502 278,081 25,144,782
Saira Ramasastry 16,891,204 484,379 25,144,782
William R. Ringo 17,092,087 283,496 25,144,782
Proposal No. 2: Ratification of Appointment of Ernst & Young LLP
The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2012 was ratified by the votes set forth in the table below:
Broker
Votes For Votes Against Abstentions Non-Votes
41,468,178 914,179 138,208 0
Item 9.01. Financial Statements and Exhibits.
(d) Exhibit.
Exhibit
Number Description
Exhibit 10.1 Sangamo BioSciences, Inc. Incentive Compensation Plan
Zincfinger - do you have advanced degrees in this area? You have a lot of knowledge and opinions related to this stock and a couple others. Trying to decipher all the dd.
Thanks.
They might need those to sell their functional HIV cure...
But the point is: 100 million is very little money compared to payments by Shire (1.6 billion) and revenues from other parnterships (existing and future) and of course from revenues based on Sangamo's own potential cures.
News about advances in all sorts of medical research for treatments using Sangamo's zincfinger technology increase almost on a daily basis.
what's happening with a secondary? 100 million bucks?
Either they are buying another company or they are going to start their own development programs v. liocensing it out.
They surely don't need the money for day to day operations.
"The study, published in Nature Medicine, advances the development of novel, cell-based therapies for the treatment of a broad range of cancers."...
"The importance of the work has been recognized with the Van Bekkum Award, the most prestigious EBMT award for the best abstract submitted to the physician's program and is selected by the EBMT Board."...
"These data represent a significant advance in maximizing the potential safety and efficacy of adoptive T-cell therapies for cancer," said Dr. Bonini. ..."ZFN-based genome editing enables us to specifically modify these redirected cells and disrupt genes that interfere with their potency and specificity, thus generating a safer, more efficacious therapeutic product."
Cancer immunotherapy uses the immune system, specifically CD8+ T-cells, that have been "redirected" to seek out and destroy tumors. These redirected T-cells are genetically engineered to express new cell surface receptors that specifically recognize tumor cells. However, CD8+ T-cells have a natural specificity for different (non-tumor) targets and the resulting competition between the natural and the tumor-targeting gene products limits the potency of this cell therapy. More importantly, it can also make the cells "self-reactive," leading to graft versus host disease (GvHD).
In this study, ZFNs were used to specifically disrupt the native T-cell receptor (TCR) genes in these tumor-directed CD8+ T-cells resulting in an enhanced immunotherapeutic product with potent anti-cancer activity coupled with the elimination of GvHD in a mouse model. The data are described in a Nature Medicine paper entitled "Editing T-cell Specificity Towards Leukemia by Zinc Finger Nucleases and Lentiviral Gene Transfer" which appears as an Advance Online Publication on the Nature Medicine website http://dx.doi.org/10.1038/nm.2700 .
All this sounds like the beginning of novel working (functional) cancer therapies!
SIAL news about ZNF
SAFC Launches CHOZN® Platform System to Accelerate Recombinant Protein Drug Development
http://ih.advfn.com/p.php?pid=nmona&article=51961910&symbol=SIAL
Side note on ZF's
Kraig Biocraft Laboratories Increases Zinc Finger Micro-Insertion Rate With Thousands of Targeted Genetic Insertions
Date : 04/10/2012 @ 6:05AM
Source : GlobeNewswire Inc.
Stock : Kraig Biocraft Laboratories, Inc (KBLB)
Quote : 0.07 0.0 (0.00%) @ 5:31AM
Kraig Biocraft Laboratories Increases Zinc Finger Micro-Insertion Rate With Thousands of Targeted Genetic Insertions
Print
Alert
Kraig Biocraft Labs (QB) (USOTC:KBLB)
Intraday Stock Chart
Today : Tuesday 10 April 2012
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB.PK) (the "Company") announces that researchers working with the Company have performed approximately five thousand zinc finger nuclease assisted micro-insertions during the past two weeks. The genetic insertions were performed in five separate and unique batches of approximately one thousand insertions per round.
"Given the targeting efficiency of the zinc finger nuclease technology and the knowledge base we developed, it is highly probable that these five rounds will produce multiple transgenics," said Company CEO, Kim Thompson. "Each of these five rounds is distinctive in terms of the genetic sequences that were used or based on some other special attribute of the genetic insertion protocol."
"From my perspective," continued Thompson, "these five thousand insertions, performed by a very distinguished group of researchers at the University of Notre Dame, consist of our most recent configurations and are the most exciting and promising to date. Each of these insertions was tailored with one goal in mind, the creation of our generation two, advanced spider silk polymer. Indeed, each round of genetic engineering insertions has the potential to create a new recombinant spider silk fiber with commercial applications."
7:30AM Sangamo BioSci announces publication in Nature Medicine demonstrating use of ZFN technology to engineer safer and more effective cancer treatments (SGMO) 4.90 : The studies were performed in the laboratory of Chiara Bonini, Head of the Experimental Hematology Unit, San Raffaele Hospital, Milan, in collaboration with Luigi Naldini, Head of TIGET, San Raffaele Hospital, and Sangamo scientists. The importance of the work has been recognized with the Van Bekkum Award. Cancer immunotherapy uses the immune system, specifically CD8+ T-cells, that have been 'redirected' to seek out and destroy tumors. These redirected T-cells are genetically engineered to express new cell surface receptors that specifically recognize tumor cells. However, CD8+ T-cells have a natural specificity for different targets and the resulting competition between the natural and the tumor-targeting gene products limits the potency of this cell therapy. It can also make the cells 'self-reactive,' leading to graft versus host disease. In this study, ZFNs were used to specifically disrupt the native T-cell receptor (TCR) genes in these tumor-directed CD8+ T-cells resulting in an enhanced immunotherapeutic product with potent anti-cancer activity coupled with the elimination of GvHD in a mouse model. The data are described in a Nature Medicine paper entitled 'Editing T-cell Specificity Towards Leukemia by Zinc Finger Nucleases and Lentiviral Gene Transfer'.
Followers
|
86
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
797
|
Created
|
09/09/04
|
Type
|
Free
|
Moderators |
http://www.sangamo.com/index.php
http://finance.yahoo.com/q/ks?s=SGMO+Key+Statistics
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company?s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington?s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |